2 weeks Ago By ABMN Staff
First County Bank CT trimmed its holdings in shares of Becton, Dickinson and Company ( NYSE:BDX – Free Report ) by 4.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,356 shares of the medical instruments supplier’s stock after selling 67 shares during the period.
First County Bank CT’s holdings in Becton, Dickinson and Company were worth $317,000 as of its most recent SEC filing. Other institutional investors and hedge funds also recently bought and sold shares of the company. Jennison Associates LLC boosted its stake in Becton, Dickinson and Company by 4.
9% in the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after purchasing an additional 18,786 shares in the last quarter. Norden Group LLC boosted its stake in Becton, Dickinson and Company by 2,086.
7% in the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock worth $12,853,000 after purchasing an additional 49,559 shares in the last quarter. Franklin Street Advisors Inc.
NC acquired a new position in Becton, Dickinson and Company in the first quarter worth $11,998,000. Avity Investment Management Inc. boosted its stake in Becton, Dickinson and Company by 3.
5% in the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock worth $40,257,000 after purchasing an additional 5,527 shares in the last quarter.
Finally, Caden Capital Partners LP raised its position in shares of Becton, Dickinson and Company by 26.7% during the fourth quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock worth $20,340,000 after acquiring an additional 17,599 shares during the last quarter.
Institutional investors and hedge funds own 86.97% of the company’s stock. Becton, Dickinson and Company Trading Up 1.
8 % NYSE BDX opened at $241.47 on Friday. The stock has a 50-day simple moving average of $236.
15 and a 200 day simple moving average of $235.52. The company has a market capitalization of $69.
79 billion, a PE ratio of 53.19, a P/E/G ratio of 1.92 and a beta of 0.
42. The company has a current ratio of 1.85, a quick ratio of 1.
36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 12 month low of $218.
75 and a 12 month high of $269.52. Becton, Dickinson and Company Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th.
Shareholders of record on Monday, September 9th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9th.
This represents a $3.80 dividend on an annualized basis and a yield of 1.57%.
Becton, Dickinson and Company’s payout ratio is 83.70%. Analyst Ratings Changes A number of research firms have recently weighed in on BDX.
Citigroup dropped their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th.
Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th.
Raymond James dropped their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd.
Evercore ISI dropped their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd.
Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock.
According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $279.50. View Our Latest Report on Becton, Dickinson and Company Becton, Dickinson and Company Company Profile ( Free Report ) Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. See Also Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter .
.
